A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain

NCT00455442 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Weight-Gain Prevention

Interventions

DRUG: Mifepristone

Sponsor

Corcept Therapeutics

Collaborators

[object Object]